Stock comparison
Eli Lilly
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 71B | LLY |
| Benjamin Graham | 86A | 76B | LLY |
| Philip Fisher | 86A | 76B | LLY |
| Peter Lynch | 74B | 62C | LLY |
| Joel Greenblatt | 78C | 46D | LLY |
| Charlie Munger | 85A | 64C | LLY |
| Terry Smith | 77C | 64C | LLY |
Side-by-side metrics
| Metric | LLY | UTHR |
|---|---|---|
| Market cap | $1T | $24.13B |
| P/E (TTM) | 36.6x | 19.2x |
| EV/EBIT | 34.1x | 15.2x |
| ROIC (TTM) | 32.06% | 18.81% |
| Gross margin | 83.51% | 86.58% |
| Net margin | 34.98% | 40.61% |
| Revenue CAGR 5y | 23.17% | 17.22% |
| EPS CAGR 5y | 40.81% | 29.84% |
| Debt / Equity | 1.4x | - |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $24.13B+98%
- ROIC (TTM)32.06%vs 18.81%+41%
- EPS CAGR 5y40.81%vs 29.84%+27%
UTHR leads on
- Debt / Equity-vs 1.4x+100%
- EV/EBIT15.2xvs 34.1x+55%
- P/E (TTM)19.2xvs 36.6x+48%
- Net margin40.61%vs 34.98%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.